T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
19m
·
JAMA Oncology Author Interviews
·
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
- T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
The episode T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy from the podcast JAMA Oncology Author Interviews has a duration of
19:57. It was first published
More episodes from JAMA Oncology Author Interviews
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
- T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.
Related Content:
- Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD.
Related Content:
- Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD.
Related Content:
- Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Atezolizumab in Combination With Carboplatin in Metastatic TNBC
Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD.
Related Content:
- Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer